Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Tumor necrosis factor gen… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy

Artikel i vetenskaplig tidskrift
Författare Lisa Ternström
Anders Jeppsson
Anne Ricksten
Folke Nilsson
Publicerad i J Heart Lung Transplant
Volym 24
Nummer/häfte 4
Sidor 433-8
ISSN 1053-2498 (Print)
Publiceringsår 2005
Publicerad vid Hjärt-kärlinstitutionen
Institutionen för laboratoriemedicin, Avdelningen för klinisk kemi/transfusionsmedicin
Sidor 433-8
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Coronary Angiography, Coronary Arteriosclerosis/*blood/etiology/radiography, Coronary Vessels/*pathology, Female, Follow-Up Studies, Gene Frequency, Genetic Markers, Graft Rejection/blood/prevention & control, Graft Survival/genetics, Heart Transplantation/*adverse effects/mortality, Humans, Immunosuppressive Agents/therapeutic use, Male, Middle Aged, Polymerase Chain Reaction, *Polymorphism, Genetic, Prospective Studies, Survival Rate, Transplantation, Homologous, Tumor Necrosis Factor-alpha/biosynthesis/*genetics
Ämneskategorier Kirurgi

Sammanfattning

BACKGROUND: Cardiac allograft vasculopathy (CAV) limits survival after cardiac transplantation. Tumor necrosis factor-alpha (TNF-alpha) may be a key factor in the development of CAV. Two bi-allelic polymorphisms associated with high TNF-alpha production have been identified in the TNF gene locus, TNFA1/2, at position -308 and TNFB1/2 at +252. We hypothesized that recipient TNFA2 and TNFB2 homozygosity is associated with the development of CAV after heart transplantation. METHODS: TNF gene polymorphisms were analyzed by multiplex fluorescent solid-phase mini-sequencing in 70 cardiac transplant recipients. Recipients homozygous for TNFA2 or TNFB2 (Group A, n = 29) were compared with recipients heterozygous or homozygous for TNFA1 and TNFB1 (Group B, n = 41). Coronary arteriography was performed annually or when indicated. Cumulative freedom from CAV and survival was calculated according to the Kaplan-Meier test. RESULTS: Mean follow-up was 3.8 +/- 0.3 years. In Group A, 11 of 29 recipients (38%) developed CAV compared with 9 of 41 (22%) in Group B (p = 0.12). Cumulative freedom from CAV at 3 years was 42% in Group A and 80% in Group B (p = 0.043). In Group A, 11 of 29 recipients (38%) died during follow-up compared with 4 of 41 (10%) in Group B (p = 0.006). Cumulative survival at 3 years was 72% in Group A and 93% in Group B (p = 0.003). CONCLUSIONS: The results suggest that TNFA2 and TNFB2 allele homozygosity is associated with cardiac allograft vasculopathy and mortality in heart transplant recipients.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?publicationId=49287
Utskriftsdatum: 2019-08-19